Shares of Opko Health Inc. (NASDAQ:OPK) hit a new 52-week low during trading on Wednesday . The company traded as low as $3.59 and last traded at $3.69, with a volume of 3760800 shares trading hands. The stock had previously closed at $3.69.
A number of research firms recently issued reports on OPK. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Opko Health has a consensus rating of “Hold” and an average target price of $13.34.
The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. The company has a market capitalization of $2,000.00, a P/E ratio of -18.79 and a beta of 1.42.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 185,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was acquired at an average cost of $3.83 per share, with a total value of $708,550.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $11,754,082.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have purchased 688,000 shares of company stock valued at $2,970,260. 40.19% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in OPK. Dimensional Fund Advisors LP boosted its position in Opko Health by 127.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after acquiring an additional 2,241,103 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in Opko Health by 611.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock worth $9,913,000 after acquiring an additional 1,242,272 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in Opko Health by 83.7% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,579,950 shares of the biotechnology company’s stock worth $17,698,000 after acquiring an additional 1,175,726 shares during the last quarter. Guggenheim Capital LLC boosted its position in Opko Health by 800.4% during the 4th quarter. Guggenheim Capital LLC now owns 605,609 shares of the biotechnology company’s stock worth $2,967,000 after acquiring an additional 538,349 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in Opko Health by 37.1% during the 4th quarter. IFP Advisors Inc now owns 1,963,601 shares of the biotechnology company’s stock worth $9,622,000 after acquiring an additional 531,088 shares during the last quarter. 22.22% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Opko Health (OPK) Reaches New 52-Week Low at $3.59” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/21/opko-health-opk-reaches-new-52-week-low-at-3-59.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.